Skip to content or view mobile version

Home | Mobile | Editorial | Mission | Privacy | About | Contact | Help | Security | Support

A network of individuals, independent and alternative media activists and organisations, offering grassroots, non-corporate, non-commercial coverage of important social and political issues.

Massive side effects of TRASYLOL known for a long time

CBGnetwork | 30.04.2008 17:11 | Health | Cambridge | World

The medical doctor Professor Dr. Juergen H. Fischer already gave warnings during the 1980's concerning the dangers of TRASYLOL. However, no action was taken. We interviewed Prof. Fischer about the long career of a sometimes deadly drug



April 30, 2008

Massive side effects of TRASYLOL known for a long time

The medical doctor Professor Dr. Juergen H. Fischer already gave warnings during the 1980's concerning the dangers of TRASYLOL. However, no action was taken. We interviewed Prof. Fischer about the long career of a sometimes deadly drug.

Question: Mr. Fischer, during what period did you work on TRASYLOL and how many studies and articles did you publish regarding this medication?

Answer: Together with colleagues and doctoral candidates I published two articles in medical magazines in 1983 and 1984 concerning side effects of TRASYLOL affecting the kidneys, one article in 2005 on its effects on the heart's coronary arteries, besides some lectures.

In 1984 the company BAYER organised a conference in Luxembourg about "New aspects of the TRASYLOL therapy". Were you invited to attend?

When I heard about the intended symposium, to which many well known heart surgeons from the German language area were invited, I called the organizer and asked whether this conference was to be one at which critics were not welcome. My published data would be particularly important regarding its use with heart surgery because we had found massive renal malfunctions in combination with TRASYLOL and hypothermia (cooling below body temperature) in connection with kidney conservation.
During heart surgery hypothermia is often knowingly induced to extend the time the heart stands still. I was then invited and presented a lecture with the title: "TRASYLOL-effects on the kidney, depending upon temperature and dosage."

What were the reactions to your talk?

It turned out that this would remain the only critical contribution. Within the session attended by all participants great interest was shown in my presentation, so I believed to have given good reasons for clinical studies to be initiated. Later I spoke on different occasions to colleagues working at clinics, but the further development is well known: German clinics predominantly issued publications in favour of TRASYLOL, sometimes with a small remark that nothing significant was found concerning the kidneys. And in the publication of all the lectures of the symposium almost every evaluation and warning of my lecture had been deleted.

In spite of this, the publication includes your conclusion "when using high dosages of Aprotinin with already damaged kidneys and particularly when reducing the temperature, the renal function should be closely supervised". Hence the dangers of TRASYLOL (active substance: Aprotinin) for the renal function was already known and published for a long time?

Contrary to the allegations of the BAYER company, at least since 1984 many German heart surgeons as well as those responsible for this drug were aware that studies on animals published by various authors from 1970 to 1984 had shown massive side effects of TRASYLOL upon kidneys. What could be a better proof than a conference book published by BAYER itself?

In the 1970s BAYER also carried out studies in East Germany as to the effects of TRASYLOL upon renal preservation. What were the results?

The supervisor for the department of experimental organ transplantation at the Charité in East Berlin, Dr. Horpacsy, mentioned in a 1975 publication positive effects of TRASYLOL upon enzyme activities. Regarding renal functions, in this publication, he only mentioned that there was no improvement in the survival of transplants in relation to TRASYLOL. When Dr. Horpacsy later heard about our very negative results of kidney preservation with TRASYLOL, he informed me that he had also found that kidneys preserved after administering TRASYLOL had shown only minimal or no function at all. As he had a subsidy contract with the BAYER company to finance his trials, he was instructed by the company's project supervisor to publish only the positive (but basically irrelevant) enzyme findings and to keep the loss of functionality of the kidneys secret.

Why did BAYER have studies carried out in East Germany at all?

Since research in Eastern Germany was centrally arranged, steered and supervised, it would naturally be interesting to know the details about the research contracts concluded in East Germany.

Prof. Schoenhoefer states about TRASYLOL, “this product always was a drug in search of an application". Would you agree with him?

This is a suitable description of the situation at the time. Since 1965 the BAYER company regularly organised conferences and published conference reports entitled "New aspects of TRASYLOL therapy". Up until Book 8 in 1975 there can be found all kinds of application trials (fruitless in the end) beginning with pancreatitis, continuing with shock, obstetrics and treatment of oedema, up to cardiac infarction.

Should TRASYLOL ever have been approved?

It is difficult to answer this question. If one reads the publication of Dr Dean Fergusson et al., which appeared in the 2005 magazine Clinical Trials, one is informed that 64 randomized clinical studies were published on TRASYLOL from 1987 to 2002, almost all to test a hypothesis examining the number of blood transfusions or the loss of blood but none of them relate to mortality. If in such studies only one single positive aspect of a drug is seen as the main aspect (and the post-surgical loss of blood reduction effect by TRASYLOL has been proven), without sufficient consideration for negative effects in the study purpose, than the licensing is to some extent understandable.

Which are the general problems concerning control of pharmaceuticals today?

The great problem with today's assessment of licensed drugs is that licensing authorities basically only accept clinical studies. Results of experimental animal studies or reports of clinical results are thus no longer taken into consideration, regardless of the importance of the reported damaging side effects. The producer of the drug is therefore free to withdraw its support for clinical studies, or to suppress the results of its own, secret studies (as happened in the case of BAYER), thus assuring the continuing sales of the drug. I believe that a change in our thinking is urgently required.

Professor Juergen Fischer is the Director of the Institute for Experimental Medicine at the University of Cologne.
Questions: Philipp Mimkes (Coalition against Bayer Dangers), www.CBGnetwork.org

Coalition against BAYER Dangers (Germany)
www.CBGnetwork.org
 CBGnetwork@aol.com
Fax: (+49) 211-333 940 Tel: (+49) 211-333 911

please send an e-mail for receiving the English newsletter Keycode BAYER free of charge. German/Italian/French/Spanish newsletters also available.

Advisory Board
Prof. Juergen Junginger, designer, Krefeld,
Prof. Dr. Juergen Rochlitz, chemist, former member of the Bundestag, Burgwald
Wolfram Esche, attorney, Cologne
Dr. Sigrid Müller, pharmacologist, Bremen
Eva Bulling-Schroeter, member of the Bundestag, Berlin
Prof. Dr. Anton Schneider, biologist, Neubeuern
Dorothee Sölle, theologian, Hamburg (died 2003)
Dr. Janis Schmelzer, historian, Berlin
Dr. Erika Abczynski, pediatrician, Dormagen

CBGnetwork
- e-mail: CBGnetwork@aol.com
- Homepage: http://www.CBGnetwork.org

Upcoming Coverage
View and post events
Upcoming Events UK
24th October, London: 2015 London Anarchist Bookfair
2nd - 8th November: Wrexham, Wales, UK & Everywhere: Week of Action Against the North Wales Prison & the Prison Industrial Complex. Cymraeg: Wythnos o Weithredu yn Erbyn Carchar Gogledd Cymru

Ongoing UK
Every Tuesday 6pm-8pm, Yorkshire: Demo/vigil at NSA/NRO Menwith Hill US Spy Base More info: CAAB.

Every Tuesday, UK & worldwide: Counter Terror Tuesdays. Call the US Embassy nearest to you to protest Obama's Terror Tuesdays. More info here

Every day, London: Vigil for Julian Assange outside Ecuadorian Embassy

Parliament Sq Protest: see topic page
Ongoing Global
Rossport, Ireland: see topic page
Israel-Palestine: Israel Indymedia | Palestine Indymedia
Oaxaca: Chiapas Indymedia
Regions
All Regions
Birmingham
Cambridge
Liverpool
London
Oxford
Sheffield
South Coast
Wales
World
Other Local IMCs
Bristol/South West
Nottingham
Scotland
Social Media
You can follow @ukindymedia on indy.im and Twitter. We are working on a Twitter policy. We do not use Facebook, and advise you not to either.
Support Us
We need help paying the bills for hosting this site, please consider supporting us financially.
Other Media Projects
Schnews
Dissident Island Radio
Corporate Watch
Media Lens
VisionOnTV
Earth First! Action Update
Earth First! Action Reports
Topics
All Topics
Afghanistan
Analysis
Animal Liberation
Anti-Nuclear
Anti-militarism
Anti-racism
Bio-technology
Climate Chaos
Culture
Ecology
Education
Energy Crisis
Fracking
Free Spaces
Gender
Globalisation
Health
History
Indymedia
Iraq
Migration
Ocean Defence
Other Press
Palestine
Policing
Public sector cuts
Repression
Social Struggles
Technology
Terror War
Workers' Movements
Zapatista
Major Reports
NATO 2014
G8 2013
Workfare
2011 Census Resistance
Occupy Everywhere
August Riots
Dale Farm
J30 Strike
Flotilla to Gaza
Mayday 2010
Tar Sands
G20 London Summit
University Occupations for Gaza
Guantanamo
Indymedia Server Seizure
COP15 Climate Summit 2009
Carmel Agrexco
G8 Japan 2008
SHAC
Stop Sequani
Stop RWB
Climate Camp 2008
Oaxaca Uprising
Rossport Solidarity
Smash EDO
SOCPA
Past Major Reports
Encrypted Page
You are viewing this page using an encrypted connection. If you bookmark this page or send its address in an email you might want to use the un-encrypted address of this page.
If you recieved a warning about an untrusted root certificate please install the CAcert root certificate, for more information see the security page.

Global IMC Network


www.indymedia.org

Projects
print
radio
satellite tv
video

Africa

Europe
antwerpen
armenia
athens
austria
barcelona
belarus
belgium
belgrade
brussels
bulgaria
calabria
croatia
cyprus
emilia-romagna
estrecho / madiaq
galiza
germany
grenoble
hungary
ireland
istanbul
italy
la plana
liege
liguria
lille
linksunten
lombardia
madrid
malta
marseille
nantes
napoli
netherlands
northern england
nottingham imc
paris/île-de-france
patras
piemonte
poland
portugal
roma
romania
russia
sardegna
scotland
sverige
switzerland
torun
toscana
ukraine
united kingdom
valencia

Latin America
argentina
bolivia
chiapas
chile
chile sur
cmi brasil
cmi sucre
colombia
ecuador
mexico
peru
puerto rico
qollasuyu
rosario
santiago
tijuana
uruguay
valparaiso
venezuela

Oceania
aotearoa
brisbane
burma
darwin
jakarta
manila
melbourne
perth
qc
sydney

South Asia
india


United States
arizona
arkansas
asheville
atlanta
Austin
binghamton
boston
buffalo
chicago
cleveland
colorado
columbus
dc
hawaii
houston
hudson mohawk
kansas city
la
madison
maine
miami
michigan
milwaukee
minneapolis/st. paul
new hampshire
new jersey
new mexico
new orleans
north carolina
north texas
nyc
oklahoma
philadelphia
pittsburgh
portland
richmond
rochester
rogue valley
saint louis
san diego
san francisco
san francisco bay area
santa barbara
santa cruz, ca
sarasota
seattle
tampa bay
united states
urbana-champaign
vermont
western mass
worcester

West Asia
Armenia
Beirut
Israel
Palestine

Topics
biotech

Process
fbi/legal updates
mailing lists
process & imc docs
tech